New answer by Medical Oncologist at Washington University School of Medicine (July 18, 2016)
This question is being addressed in clinical trials of CDK4/6 inhibitors. In preclinical studies, CDK4/6 inhibition induces senescence in HER2 positive breast cancer cell line...